Modelling the Impact of Antiretroviral Use in Resource-Poor Settings
暂无分享,去创建一个
[1] B. Masquelier,et al. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. , 2005, AIDS research and human retroviruses.
[2] L. Palombi,et al. HIV/AIDS in Africa: treatment as a right and strategies for fair implementation. False assumptions on the basis of a minimalistic approach. , 2005, AIDS (London).
[3] F. Goebel. Immune Reconstitution Inflammatory Syndrome (IRIS)—Another New Disease Entity Following Treatment Initiation of HIV Infection , 2005, Infection.
[4] David P. Wilson,et al. Designing Equitable Antiretroviral Allocation Strategies in Resource-Constrained Countries , 2005, PLoS medicine.
[5] J. Salomon,et al. Integrating HIV Prevention and Treatment: From Slogans to Impact , 2005, PLoS medicine.
[6] N. Hearst,et al. Condom promotion for AIDS prevention in the developing world: is it working? , 2004, Studies in family planning.
[7] J. Mukherjee,et al. Tackling HIV in resource poor countries , 2003, BMJ : British Medical Journal.
[8] T. Flanigan,et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India , 2003, AIDS.
[9] N. Livesley,et al. Antiretroviral therapy in a primary care clinic in rural South Africa. , 2003, AIDS.
[10] A. Calmy,et al. Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières , 2003, AIDS.
[11] Richard D Moore,et al. Survival in an Urban HIV‐1 Clinic in the Era of Highly Active Antiretroviral Therapy: A 5‐Year Cohort Study , 2003, Journal of acquired immune deficiency syndromes.
[12] Maria Deloria-Knoll,et al. Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata , 2003, Annals of Internal Medicine.
[13] Kent J Weinhold,et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. , 2003, The Journal of infectious diseases.
[14] Evan Wood,et al. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? , 2003, AIDS.
[15] Simon D W Frost,et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. , 2003, The Journal of infectious diseases.
[16] G. d’Ettorre,et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy , 2003, Journal of medical virology.
[17] A. Karpas,et al. Characterization of nef gene of HIV type 1 in highly active antiretroviral therapy treated AIDS patients with discordance between viral load and CD4+ T cell counts. , 2002, AIDS research and human retroviruses.
[18] H. Gershengorn,et al. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? , 2002, The Lancet. Infectious diseases.
[19] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[20] P. Weidle,et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.
[21] A. Harries,et al. Preventing antiretroviral anarchy in sub-Saharan Africa , 2001, The Lancet.
[22] P. Massip,et al. Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of virology.
[23] S. Kippax,et al. Modelling the effect of combination antiretroviral treatments on HIV incidence , 2001, AIDS.
[24] R. Selik,et al. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. , 2001, JAMA.
[25] R Hoh,et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.
[26] K. Hertogs,et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure , 2000, AIDS.
[27] M. Boily,et al. Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda , 2000, AIDS.
[28] Noah Kiwanuka,et al. Mortality associated with HIV infection in rural Rakai District, Uganda , 2000, AIDS.
[29] T. Quinn,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.
[30] J. Gallant,et al. Strategies for long-term success in the treatment of HIV infection. , 2000, JAMA.
[31] R. Anderson,et al. Both a ‘magic bullet’ and good aim are required to link public health interests and health care needs in HIV infection , 2000, Nature Medicine.
[32] H. Gershengorn,et al. A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.
[33] M A Wainberg,et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use , 2000, AIDS.
[34] V. Calvez,et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). , 2000, JAMA.
[35] M. Hirsch,et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.
[36] E. Rosenberg,et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. , 1999, JAMA.
[37] Richard A. Loftus,et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.
[38] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[39] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[40] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[41] Anne M Johnson,et al. Assessing participation bias in a sexual behaviour survey: implications for measuring HIV risk , 1997, AIDS.
[42] D. Weissman,et al. Immunopathogenic Mechanisms of HIV Infection , 1996, Annals of Internal Medicine.
[43] A. Lazzarin,et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. , 1994, Archives of internal medicine.
[44] Hadi Dowlatabadi,et al. Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .
[45] D. Ho,et al. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals , 1993, Journal of virology.
[46] M. Moroni. Genotypic resistance tests for the management of patients with viro-immunological discordant response to highly active antiretroviral therapy. , 2003, Scandinavian Journal of Infectious Diseases. Supplementum.
[47] J. Cleland,et al. Reliability and validity of survey data on sexual behaviour. , 1994, Health transition review : the cultural, social, and behavioural determinants of health.